Timothy Rolph, Chief Scientific Officer at Akero Therapeutics, Inc. (AKRO), sold 509 shares at $55.16 ($28K) on 2023-06-13, disclosed to the SEC on 2023-06-15.
Scheduled sale ($28k) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| AKRO | SELL | 2025-09-10 | $1.1M | — | Filing → |
| AKRO | SELL | 2025-08-07 | $1.2M | — | Filing → |
| AKRO | SELL | 2025-07-09 | $1.2M | — | Filing → |